Peptide Comparison
Dulaglutide vs Liraglutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
GLP-1 agonist + insulin or sulfonylureas: High risk per peptide research literature. Hypoglycemia risk: GLP-1 enhances glucose-dependent insulin secretion; stacking with exogenous insulin or secretagogues can drive severe lows.
Data-derived verdict
Dulaglutide and Liraglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Liraglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Liraglutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: nausea; thyroid c-cell tumor warning. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Dulaglutide | Liraglutide | |
|---|---|---|
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1 receptor agonist fused to human IgG4 Fc | GLP-1R agonist; albumin-binding fatty acid extends half-life |
| Route | SC injection | SC injection |
| Half-life | ~5 days | ~13 hrs |
| Dosage (research) | 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials) | 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label) |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 311 indexed | 321 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning | Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Dulaglutide or Liraglutide?
Dulaglutide and Liraglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Liraglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Liraglutide's evidence base is currently denser.
What is the difference between Dulaglutide and Liraglutide?
Dulaglutide is classed as GLP-1 receptor agonist; Liraglutide is classed as GLP-1 receptor agonist. Reported mechanism: Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc; Liraglutide, GLP-1R agonist; albumin-binding fatty acid extends half-life. Reported half-life: Dulaglutide, ~5 days; Liraglutide, ~13 hrs. Routes in published studies: Dulaglutide, SC injection; Liraglutide, SC injection.
Which has stronger evidence, Dulaglutide or Liraglutide?
Dulaglutide and Liraglutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Dulaglutide is graded FDA-Approved, with 41 cited sources on its reference page and 311 indexed studies. Liraglutide is graded FDA-Approved, with 64 cited sources on its reference page and 321 indexed studies.
Which is more accessible, Dulaglutide or Liraglutide?
Both Dulaglutide and Liraglutide are FDA-approved drugs. Catalog status: Dulaglutide, Prescription; Liraglutide, Prescription.
Are Dulaglutide and Liraglutide ever combined?
Dulaglutide and Liraglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…